Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States

Abstract

Key Points Over the last decade, allogeneic HCT has been increasingly administered in the United States to adults aged 70 and older with hematologic malignancies. Allogeneic transplant outcomes were reasonable; high comorbidity and ablative conditioning regimens were associated with inferior outcomes.